| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
260.58(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
172,562 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,440,488 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
8 |
21 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zaderej Karen L. |
CEO |
• • – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
29,993 |
647,244 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-02-18 |
4 |
D |
$14.68 |
$79,698 |
D/D |
(5,429) |
631,229 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$13,564 |
D/D |
(924) |
4,802 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,181 |
5,153 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,930 |
4,545 |
|
- |
|
| Freitag Gregory Gene |
General Counsel |
• • – |
2020-02-18 |
4 |
D |
$14.68 |
$22,475 |
D/D |
(1,531) |
106,484 |
|
- |
|
| Freitag Gregory Gene |
General Counsel |
• • – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,160 |
107,013 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$6,459 |
D/D |
(440) |
6,521 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,326 |
6,961 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$5,784 |
D/D |
(394) |
2,932 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,326 |
3,326 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$27,143 |
D/D |
(1,849) |
48,526 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
6,230 |
48,877 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2020-02-18 |
4 |
D |
$14.68 |
$13,740 |
D/D |
(936) |
1,595 |
|
- |
|
| Sandberg Eric |
Chief Commercial Officer |
• – – |
2020-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,531 |
2,531 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-01-01 |
4 |
D |
$17.34 |
$175,342 |
D/D |
(10,112) |
622,680 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
632,792 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2020-01-01 |
4 |
D |
$17.89 |
$35,762 |
D/D |
(1,999) |
45,592 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2020-01-01 |
4 |
OE |
$2.75 |
$35,750 |
D/D |
13,000 |
47,591 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2019-12-18 |
4 |
D |
$16.73 |
$3,062 |
D/D |
(183) |
26,041 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2019-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
26,224 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2019-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
599,530 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2019-12-18 |
4 |
D |
$16.73 |
$3,062 |
D/D |
(183) |
2,127 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2019-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
2,310 |
|
- |
|
| Freitag Gregory Gene |
General Counsel |
• • – |
2019-12-18 |
4 |
D |
$16.73 |
$9,486 |
D/D |
(567) |
101,543 |
|
- |
|
529 Records found
|
|
Page 13 of 22 |
|
|
0.16 (2.62%) 
